New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NattoPharma appoints head of R&D

The Board of publicly traded company NattoPharma ASA, announces today that Vladimir Badmaev MD, PhD has accepted the appointment as head of research and development at NattoPharma. Dr. Badmaev will lead NattoPharma’s research and development program to support its premium brand of vitamin K2, MenaQ7, and also head the development of a line of biotechnology products based on fermentation technologies and a solvent-free green technology to broaden the food, nutraceutical and pharmaceutical applications of NattoPharma products.


“Dr. Badmaev is a much welcome addition to the NattoPharma team,” stated NattoPharma CEO Frode Bohan. “He has pioneered many leading ingredients in the natural products industry in his career, and his proven record of guiding product development will surely help us grow our Vitamin K2 franchise, as well as creating additional product offerings as we expand our biotechnology base.”


Dr. Badmaev received his MD and PhD (immunopharmacology) in Bialystok, Poland, and training in clinical and anatomical pathology at Kings County Hospital and Downstate Medical Center, New York (1982-1985). He is the author/coauthor of more than 70 scientific and popular scientific articles, 13 books, 13 U.S. and International patents and nine successful IND applications with the FDA, several self-affirmed GRAS documents and NDI applications.


Prior to appointment with NattoPharma Dr. Badmaev has successfully served as a vice president and medical and scientific director with Sabinsa Inc. and PLThomas Inc. respectively, assisting those companies in building pre-clinical and clinical research on the innovative standardized food supplements. Recently, in a joint venture with a group of international investors he established American Medical Holdings, Inc., dedicated to developing natural and synthetic pharmaceuticals which he terms “Interactive nutrients.”


Dr. Badmaev is the 2004 recipient of the New Jersey R&D Council Thomas Alva Edison Award for ForsLean, an ingredient promoting lean body mass. He is the 2005 recipient of the Award for Bioperine in promoting nutrient bioavailability and the 2009 recipient of Thomas Alva Edison Award for composition of Garcitrin natural and synthetic HCA for body weight management. Dr. Badmaev participated in the following Medical/Scientific Societies: International Society of Immunopharmacology (1982), American Association of Clinical Pathologists (1983), American Medical Association (1984), Research and Development Council of New Jersey (1996).


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.